Clinical Trials /

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

NCT02268370

Description:

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced. This research is being done because dasatinib has been shown to achieve a greater response in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately 300 times more potent than imatinib, and it is possible that a greater response can be achieved by dasatinib than by imatinib.

Related Conditions:
  • Chronic Myeloid Leukemia
Recruiting Status:

Active, not recruiting

Phase:

Phase 2

URL:

https://clinicaltrials.gov/show/NCT02268370

Trial Eligibility

Document

Title

  • Brief Title: Treatment-free Remission Accomplished With Dasatinib in Patients With CML
  • Official Title: Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Clinical Trial IDs

  • ORG STUDY ID: BMS CA180-543
  • SECONDARY ID: OZM-056
  • NCT ID: NCT02268370

Conditions

  • Chronic Myeloid Leukemia

Interventions

DrugSynonymsArms
DasatinibSprycelDasatinib

Purpose

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced. This research is being done because dasatinib has been shown to achieve a greater response in a much higher proportion of patients as compared to imatinib. Dasatinib is approximately 300 times more potent than imatinib, and it is possible that a greater response can be achieved by dasatinib than by imatinib.

Detailed Description

      This is an open label, single arm Phase II trial that will examine how safe and effective it
      will be for patients with chronic myeloid leukemia (CML) to discontinued first line tyrosine
      kinase inhibitor (TKI) therapy.

      The main goal of this study is to determine the potential role of dasatinib (the study drug)
      in helping patients with CML attain a sustained treatment free remission.

      During this study the safety and tolerability of Dasatinib will be evaluated by means of drug
      related toxicity, adverse event reports, physical examinations and laboratory safety
      evaluations.

      The study period for an individual patient is expected to be approximately between 30-72
      months.

      A total of 135 patients will be recruited from 10 Canadian centres.

Trial Arms

NameTypeDescriptionInterventions
DasatinibOtherThis research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib. Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years. If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years. If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib.
  • Dasatinib

Eligibility Criteria

        Inclusion Criteria:

          1. Diagnosis of CML

          2. Treatment of chronic phase CML treated for a minimum of three years exclusively with
             imatinib

          3. Levels of BCR-ABL by RQ-PCR with ≥ 4.5 log reduction from baseline

          4. Provide written informed consent

          5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          6. Age >18 years.

          7. Adequate organ liver and renal functions

          8. Normal serum levels (within normal limits)

        Exclusion Criteria:

          1. Prior treatment with a TKI (except for imatinib, hydroxyurea, anagrelide or
             interferon)

          2. Taking any medications or substances known to affect CYP3A4.

          3. Concurrent medical condition which may increase the risk of toxicity

          4. History of significant bleeding disorder unrelated to cancer

          5. Cardiac Symptoms

          6. Clinically significant hypokalemia or hypomagnesemia that cannot be corrected prior to
             dasatinib administration
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Molecular Remission
Time Frame:change from baseline in Molecular Profile at 12 months
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Active, not recruiting
Lead Sponsor:University Health Network, Toronto

Last Updated

November 29, 2019